StockData

Arcturus Therapeutics vs uniQure

ARCT and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARCT and QURE compare

uniQure is the larger company, worth 6.4 times as much as Arcturus Therapeutics ($1.4B against $227M).

uniQure grew revenue faster over the last twelve months (30.2% versus −76.0% for Arcturus Therapeutics).

Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −318% compared with −1351% at uniQure.

Arcturus Therapeutics scores higher on the StockData Score (9 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARCTQURE
Size and price
Market cap$227M$1.4B
Share price$7.97$20.78
Change, 1 year9.6%−30.5%
Change, 5 years−80.0%−27.9%
Beta (5Y)2.033.14
Employees111221
StockData Score
Total score9 (better)4
Valuation score2 (better)0
Growth score02 (better)
Performance score2 (better)0
Health score5 (better)2
Dividend score00
Valuation
P/S7.7× (better)77.2×
P/B1.3× (better)4.4×
FCF yield−32.1%−11.2% (better)
Fair value$8.83$6.42
Margin of safety9.8% (better)−224%
Growth
Revenue growth (TTM)−76.0%30.2% (better)
Revenue growth, 5Y average53.8% (better)−15.6%
Profitability
Gross margin–92.5%
Operating margin−348% (better)−1072%
Net margin−318% (better)−1351%
FCF margin−248% (better)−865%
Return on equity−46.3% (better)−158%
Return on invested capital−1084%–
Financial health
Debt / equity0.000.15 (better)
Interest coverage–−3.4×
Current ratio5.8810.01 (better)
Altman Z-score−1.44−0.51 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.9%96.0%
Held by insiders8.1%2.1%
Insider net buying, 12 months–−$20.2M
Short interest, % of float20.7%12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.